Earnings Estimates Moving Higher for Vanda (VNDA): Time to Buy?
Tesla, Inc. TSLA incurred an adjusted loss of $3.35 per share in first-quarter 2018, narrower than the Zacks Consensus Estimate of the loss of $3.37. The company reported loss of $1.33 per share in the prior-year quarter.
The reported net loss in the quarter under review was $784.6 million compared with the year-ago net loss of $397.2 million.
Revenues increased to $3.41 billion from $2.70 billion registered in first-quarter 2017. The figure surpassed the Zacks Consensus Estimate of $3.17 billion.
Tesla produced 34,494 vehicles in first-quarter 2018, up 40% sequentially. This happens to be the most productive quarter in the history of Tesla. Out of total vehicles produced, 24,728 were Model S and Model X while 9,766 were Model 3. Also, during the reported quarter, the company delivered 29,997 vehicles which including 21,815 Model S and Model X vehicles along with 8,182 Model 3 vehicles.
Total automotive revenues, which include revenues from automotive sales and leasing, increased 19% year over year to $2.74 billion in the reported quarter. The rise was due to Model 3 deliveries and the adoption of new accounting standards.
Energy generation and storage revenues soared from $213.9 million in first-quarter 2017 to $410 million in the reported quarter. The rise was mainly due to considerable growth of energy-storage deployments.
Services and other revenues increased 37% year over year, primarily due to higher used-car sales.
Tesla’s first-quarter 2018 automotive gross margin was 18.8%, declining 904 basis points (bps) from first-quarter 2017.
Energy generation and storage gross margin declined 2,061 bps on a year-over-year basis to 8.5%.
Tesla had cash and cash equivalents of $2.67 billion as of Mar 31, 2018, compared with $3.37 billion, as of Dec 31, 2017.
Net cash used in operating activities amounted to $398.4 million in first-quarter 2018 compared with net cash provided of $509.9 million in fourth-quarter 2017. Capital expenditures jumped to $655.7 million from $552.6 million in the year-ago quarter.
In first-quarter 2018, Tesla opened nine new stores and service locations. The company also opened 77 new Supercharger locations, reaching the global total to 1,205.
Model 3 Update
During the second half of first-quarter 2018, Tesla made solid progress in Model 3 production and has been able to carry this trend into second-quarter 2018. In the prior week of this earnings release, the company produced 2,270 Model 3 and 2,024 Model S and Model X vehicles, setting a new record. The company continues to target Model 3 production of about 5,000 per week in about two months.
Tesla, Inc. Price, Consensus and EPS Surprise
Tesla, Inc. Price, Consensus and EPS Surprise | Tesla, Inc. Quote
The company expects to shut down production for about 10 days in second-quarter 2018 (including the shutdown in April) to address bottlenecks and raise production.
Tesla expects to deliver around 100,000 units of Model S and Model X in 2018, similar to the prior-quarter guidance.
Energy generation and storage revenues are likely to improve significantly in 2018 due to expanding capacity for Powerwall and Powerpack products at Gigafactory 1.
Zacks Rank & Key Picks
Tesla currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the auto space are Visteon Corporation VC, Wabash National Corporation WNC and Fiat Chrysler Automobiles N.V. FCAU. Visteon and Wabash National currently carry a Zacks Rank #2 (Buy) while Fiat Chrysler sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Visteon has expected long-term growth rate of 16.6%. In the last three months, shares of the company have gained 3.8%.
Wabash National has expected long-term growth rate of 21.5%. Shares of the company have risen 5.2% in the last six months.
Fiat Chrysler has expected long-term growth rate of 23.7%. In the last six months, shares of the company have gained 24.8%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profit.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Tesla, Inc. (TSLA) : Free Stock Analysis Report
Fiat Chrysler Automobiles N.V. (FCAU) : Free Stock Analysis Report
Visteon Corporation (VC) : Free Stock Analysis Report
Wabash National Corporation (WNC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research